Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vafidemstat - Oryzon Genomics

Next Previous
Drug Profile

Vafidemstat - Oryzon Genomics

Alternative Names: ORY-2001

Latest Information Update: 19 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oryzon
  • Developer Institute of Medical and Molecular Genetics; Oryzon
  • Class Amines; Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Cyclopropanes; Neuroprotectants; Nootropics; Oxadiazoles; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Aggression; Alzheimer's disease; Borderline personality disorders; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Schizophrenia
  • No development reported Autistic disorder; Dementia; Huntington's disease; Parkinson's disease; Telomeric 22q13 Monosomy Syndrome

Most Recent Events

  • 15 Oct 2026 Oryzon Genomics has received new decisions to grant patent for Vafidemstat in South Korea, the Philippines, New Zealand and Mexico
  • 15 Oct 2026 Oryzon Genomics has patents granted for Vafidemstat in Australia, Canada, Europe, Hong Kong, Japan, Malaysia, Mexico, Russia, Singapore, South Africa and the United States
  • 28 Sep 2026 EMA authorises the CTA to initiate the phase II HOPE-2 study for vafidemstat for Telomeric 22q13 Monosomy Syndrome

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top